Zacks.com on MSN5h
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLCAstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its ...
Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...
GlobalData on MSN4h
CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLCThe European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...
Zacks.com on MSN1d
CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLCJohnson & Johnson JNJ announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving ...
Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...
The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung ...
For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated ...
Male sex was also shown to be an independent risk factor for longer hospital stays and increased hospitalization costs at ...
Collaboration to harness Lunit SCOPE Genotype Predictor for rapid and convenient prediction of non-small cell lung cancer ...
has recommended approval of Lazcluze in combination with Rybrevant for the first-line treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC). The CHMP ...
During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in ...
Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback